[go: up one dir, main page]

AR022839A1 - Antagonistas de la integrina alfavbeta3 en combinacion con agentes quimioterapeuticos - Google Patents

Antagonistas de la integrina alfavbeta3 en combinacion con agentes quimioterapeuticos

Info

Publication number
AR022839A1
AR022839A1 ARP000100976A ARP000100976A AR022839A1 AR 022839 A1 AR022839 A1 AR 022839A1 AR P000100976 A ARP000100976 A AR P000100976A AR P000100976 A ARP000100976 A AR P000100976A AR 022839 A1 AR022839 A1 AR 022839A1
Authority
AR
Argentina
Prior art keywords
combination
chemotherapeutic agents
antagonists
alfavbeta3
integrin
Prior art date
Application number
ARP000100976A
Other languages
English (en)
Original Assignee
Searle & Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Searle & Co filed Critical Searle & Co
Publication of AR022839A1 publication Critical patent/AR022839A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/06—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D239/08—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms directly attached in position 2
    • C07D239/12—Nitrogen atoms not forming part of a nitro radical
    • C07D239/14—Nitrogen atoms not forming part of a nitro radical with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached to said nitrogen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Inorganic Chemistry (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente se refiere a compuestos de Formula (1) y sales aceptables para uso farmacéutico e isomeros de los mismos administrados en combinacion conagentes quimioterapéuticos.
ARP000100976A 1999-03-04 2000-03-03 Antagonistas de la integrina alfavbeta3 en combinacion con agentes quimioterapeuticos AR022839A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/262,725 US6372719B1 (en) 1998-03-04 1999-03-04 ανβ3 integrin antagonists in combination with chemotherapeutic agents

Publications (1)

Publication Number Publication Date
AR022839A1 true AR022839A1 (es) 2002-09-04

Family

ID=22998755

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP000100976A AR022839A1 (es) 1999-03-04 2000-03-03 Antagonistas de la integrina alfavbeta3 en combinacion con agentes quimioterapeuticos

Country Status (6)

Country Link
US (2) US6372719B1 (es)
EP (1) EP1161280A1 (es)
JP (1) JP2002538177A (es)
AR (1) AR022839A1 (es)
AU (1) AU3595100A (es)
WO (1) WO2000051686A1 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2161373T3 (es) * 1995-08-30 2001-12-01 Searle & Co Derivados de meta-guanidina, urea, tiourea o acido azaciclico-aminobenzoico como antagonistas de integrinas.
US6451784B1 (en) * 1996-12-30 2002-09-17 Battellepharma, Inc. Formulation and method for treating neoplasms by inhalation
WO2000038719A1 (en) * 1998-12-23 2000-07-06 G.D. Searle & Co. Use of a matrix metalloproteinase inhibitor and an integrin antagonist in the treatment of neoplasia
US7740841B1 (en) 2000-01-28 2010-06-22 Sunnybrook Health Science Center Therapeutic method for reducing angiogenesis
WO2004060376A1 (en) * 2002-12-20 2004-07-22 Pharmacia Corpration The r-isomer of beta amino acid compounds as integrin receptor antagonists derivatives
US20100222406A1 (en) * 2007-09-11 2010-09-02 University Of Virginia Patent Foundation T Type Calcium Channel Blockers and the Treatment of Diseases
EP1778619B1 (en) * 2004-08-20 2012-04-04 University Of Virginia Patent Foundation T type calcium channel inhibitors
US8426568B2 (en) 2006-05-22 2013-04-23 University Of Virginia Patent Foundation Rhamnose substituents of SL0101 and therapeutic uses thereof
US20110230423A1 (en) * 2008-11-20 2011-09-22 Martin Andreas Picard Therapy and medicament using integrin ligands for treating cancer
US8748618B2 (en) 2009-05-13 2014-06-10 University Of Virginia Patent Foundation Inhibitors of inv(16) leukemia
SG10201501496TA (en) 2010-03-01 2015-04-29 Tau Therapeutics Llc Cancer diagnosis and imaging
US8716226B2 (en) 2012-07-18 2014-05-06 Saint Louis University 3,5 phenyl-substituted beta amino acid derivatives as integrin antagonists
CN104640857B (zh) 2012-07-18 2017-07-04 圣路易斯大学 作为整合素拮抗剂的β氨基酸衍生物
ES2806276T3 (es) 2015-12-30 2021-02-17 Univ Saint Louis Derivados de ácido aminobenzoico meta-azaciclicos como antagonistas pan-integrina
KR20190032370A (ko) * 2016-07-27 2019-03-27 유니버시티 오브 버지니아 페이턴트 파운데이션 암을 치료하기 위한 복합 요법
EP3641783A4 (en) 2017-06-22 2021-03-10 University Of Virginia Patent Foundation Proton activated atomic medicine
BR112022023058A2 (pt) 2020-05-14 2022-12-20 Ube Corp Derivado de 1,4,5,6-tetrahidropirimidin-2-amina
WO2023085396A1 (ja) 2021-11-12 2023-05-19 Ｕｂｅ株式会社 アルポート症候群を治療または予防するための医薬組成物

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6193163A (ja) * 1984-10-12 1986-05-12 Ishihara Sangyo Kaisha Ltd Ｎ−ベンゾイル−ｎ′−フエニルウレア系化合物、それらの製造方法並びにそれらを含有する抗癌剤
US5256812A (en) * 1989-01-31 1993-10-26 Hoffmann-La Roche Inc. Carboxamides and sulfonamides
US5753230A (en) * 1994-03-18 1998-05-19 The Scripps Research Institute Methods and compositions useful for inhibition of angiogenesis
US5518732A (en) * 1995-02-14 1996-05-21 Chiron Vision, Inc. Bio-erodible ophthalmic shield
US6013651A (en) * 1995-08-30 2000-01-11 G. D. Searle & Co. Meta-azacyclic amino benzoic acid compounds and derivatives thereof
ES2161373T3 (es) 1995-08-30 2001-12-01 Searle & Co Derivados de meta-guanidina, urea, tiourea o acido azaciclico-aminobenzoico como antagonistas de integrinas.
UA60311C2 (uk) 1996-10-02 2003-10-15 Смітклайн Бічам Корпорейшн Антагоністи рецептора вітронектину, спосіб одержання цих сполук та фармацевтична композиція
AU729869B2 (en) 1997-01-17 2001-02-15 Merck & Co., Inc. Integrin antagonists

Also Published As

Publication number Publication date
WO2000051686A1 (en) 2000-09-08
US20030050250A1 (en) 2003-03-13
JP2002538177A (ja) 2002-11-12
US6372719B1 (en) 2002-04-16
EP1161280A1 (en) 2001-12-12
AU3595100A (en) 2000-09-21

Similar Documents

Publication Publication Date Title
AR022839A1 (es) Antagonistas de la integrina alfavbeta3 en combinacion con agentes quimioterapeuticos
ES2552639T3 (es) Uso combinado de valsartán y bloqueantes de los canales de calcio para fines terapéuticos
CO4340681A1 (es) Procedimientos de uso para la inhibicion de la perdida osea y la disminucion del colesterol en suero
ECSP034774A (es) Pirazolopirimmidinas como agentes terapeuticos
UY25242A1 (es) Inhibidores de benzotiazol de la proteína tirosina cinasa
ES2091877T3 (es) Uso de antagonistas de la angiotensina ii para la fabricacion de un medicamento para el tratamiento de la hiperuricemia.
AR031973A1 (es) Agonistas de los receptores beta2-adrenergicos, una composicion farmaceutica, y uso de dichos agonistas para la manufactura de un medicamento
NO20030744D0 (no) Nye fenylalaninderivater
RU95109100A (ru) Производные ксантина, смесь их изомеров или отдельные изомеры и их фармакологически переносимые соли и фармацевтическая композиция с антагонистической в отношении аденозина активностью на их основе
AR008878A1 (es) Antagonistas del receptor de vitronectina, un metodo para su preparacion, una composicion farmaceutica que los contiene y el uso de las mismas para la preparacion de un medicamento.
SV1997000049A (es) Conjugados de interferones ref. 12614 sv
UY27222A1 (es) Pirazolopirimidinas como agentes terapéuticos
EA200200571A1 (ru) Новая композиция и ее применение
UY26258A1 (es) Derivados de 8-fenil-6,9-dihidro-[1,2,4] triazolo [3,4-i] purin-5-ona.
AR030857A1 (es) Derivados nitroso de difenolaminas, composiciones farmaceuticas que los contienen y su uso en la preparacion de productos medicinales
PA8506301A1 (es) Cristal de 4- carboxamino- 1,2,3,4,- tetrahidroquinolina 2-sustituida
BR0012901A (pt) Medicamentos de ß - carbolina
BR9712816A (pt) Derivados de benzamidina e seu uso como medicamentos com uma atividade antagonista ltb4
AR029447A1 (es) Derivados de arilcarbonilamino o indanos, composicion farmaceutica que los comprenden y el uso de los mismos para la manufactura de medicamentos
ES2135342B1 (es) Uso del raloxifeno o una sal o salvato del mismo en la preparacion de un medicamento para prevenir el cancer de mama.
AR003451A1 (es) Derivados de piperazina, una composicion farmaceutica que los comprende, el uso de los mismos y un metodo para su preparacion.
MX9300399A (es) Derivados heterotriciclicos.
ES2020171T3 (es) Eteres de 1-bencil-3-hidroximetilindazol con 2-hidroxiacidos alifaticos.
BR9916887A (pt) Uso de derivados de pirimidina
CR6398A (es) Antagonistas de 5ht1 para terapia antidepresiva

Legal Events

Date Code Title Description
FB Suspension of granting procedure